GNS561

DRUG3 trials

Sponsors

Centre Hospitalier Universitaire De Grenoble, Genoscience Pharma

Conditions

COVID-19Cholangiocarcinoma, IntrahepaticHepatocellular Carcinomaunresectable hepatocellular carcinoma

Phase 1

Study of GNS561 in Patients With Liver Cancer

TerminatedNCT03316222

Genoscience PharmaCholangiocarcinoma, Intrahepatic, Hepatocellular Carcinoma

Start: 2018-04-04End: 2022-04-25Updated: 2022-05-02

Phase 2

A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

Genoscience PharmaCOVID-19

Start: 2020-11-18End: 2021-12-30Target: 178Updated: 2021-07-28

Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER

CompletedCTIS2022-502078-17-00

Centre Hospitalier Universitaire De Grenobleunresectable hepatocellular carcinoma

Start: 2022-12-15End: 2024-03-08Target: 196Updated: 2023-08-22

Related Papers

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

2022-02-1522 citations

First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies.

Journal of Clinical Oncology2021-05-205 citations